The Funding Gap, 2026
Where the money for women's health actually goes — and why everything after 40 falls through the crack.
By Delaney Cassidy · Category: The Gap
Every time someone hears these numbers, they push back with the same sentence: “But there's tons of women's health research now.” There is more than there was. And almost none of it is for you.
In 2026, for the first time, someone actually measured where the money goes. The picture is worse than “underfunded.” It's funded for the wrong decades of a woman's life.
6% — for half the population
Women are just over half the human race. Women's health receives about 6% of private healthcare investment. That's the whole category — every condition that affects women, funded at roughly six cents on the dollar.
90% of that goes to three things
Here's the number that answers the “but there's plenty of research” objection once and for all. Of that small slice, roughly 90% flows into just three areas: women's cancers, reproductive health, and maternal health.
All three matter enormously. But notice what they have in common — they're mostly about the years when a woman is having babies, or about cancer. Endometriosis, PCOS, and menstrual health, conditions that shape decades of life, together get less than 2% of women's health investment.
Women's health gets ~6% of investment. Ninety percent of that goes to cancer, fertility, and pregnancy. Everything after 40 competes for the scraps.
Menopause? Perimenopause? Bone health, the midlife heart, the brain? They fall in the gap after fertility and before the cancers of old age — the decades the funding map simply doesn't cover.
The research number that says it out loud
If you want the version in plain federal dollars: the NIH spends about $56 million a year on menopause research — roughly one-tenth of one percent of its budget — for a transition that will affect essentially every woman who lives long enough. For scale, endometriosis, which affects 190 million women worldwide, has drawn about $44 million in startup funding, while erectile dysfunction drew about $1.24 billion. Same category of “quality-of-life” condition. Twenty-eight times the money.
How the money got this crooked
None of this was a single villain's decision. It's the accumulation of a hundred smaller ones. Research follows funding; funding follows markets and mortality; and for a long time women's midlife health sat in the blind spot of both. It isn't a disease that kills fast enough to command a cancer budget, and it isn't tied to fertility, so it fell outside the reproductive-health envelope that captures most women's-health dollars. It's simply the long, unglamorous middle of a woman's life — and the middle doesn't get funded.
Layer on top of that a research culture that, until embarrassingly recently, treated the male body as the default and the female body as a complicated variation to be studied “later.” Later is the decade you are standing in right now.
The part that isn't charity
Here's what makes the neglect almost funny, in a bleak way: closing the women's health gap isn't a cost. It's the largest untapped market nobody's serving. Analysts at McKinsey and the World Economic Forum estimate that closing it would add at least $1 trillion a year to the global economy by 2040 — largely by giving women back the roughly 75 million healthy life-years they lose annually to conditions no one bothered to study.
And women spend about 25% more of their lives in poor health than men. Not more years alive — more years unwell. That's not biology being unfair. That's a research map with a hole in it exactly where midlife women stand. Not to mention, the financial impact of losing women in the workforce - those numbers are staggering! We will tackle that in a soon-to-be-published blog. Stay with us!
The comparison nobody wants to print
If you want the single number that says the quiet part out loud, it's this one: erectile dysfunction, which is genuinely worth treating, attracted roughly $1.24 billion in startup funding. Endometriosis — a disease that causes decades of pain for 190 million women — attracted about $44 million. Twenty-eight to one. Both are quality-of-life conditions. Only one of them happens to men. You don't need a conspiracy to explain that gap; you only need to notice whose discomfort the market has historically decided was urgent.
Menopause sits in the same shadow — not because it's rare (it is the single most universal transition in half the human population), but because the people it happens to spent a very long time being told to handle it quietly and not make a fuss. The funding map is what that instruction looks like in dollars.
Why naming it is the whole point
You cannot fix a gap nobody will measure. For years, the answer to “why is menopause so poorly understood?” was a shrug. Now, in 2026, there are numbers: 6%, 90% into three areas, under 2% for the rest, $56 million, twenty-eight to one. Numbers can be argued with. Shrugs can't.
This is why we keep saying it out loud — not to make you despair, but to hand you the receipts or the data. Because the women who know these numbers are the ones who walk into the exam room, and the boardroom, and the ballot box, and refuse to be told the gap is just how it is.
What a number actually buys you
It's fair to ask: what's the point of memorizing funding statistics when you just want to feel better on a Tuesday? Here's the point. Every one of these numbers is a sentence you can say in a room where you'd otherwise be dismissed. “Menopause research is 0.12% of the NIH budget” is why your doctor wasn't taught this — so it isn't personal. “Ninety percent of women's health funding goes to fertility and cancer” is why there's no clear protocol and no specialist down the hall — so the gaps in your care aren't your imagination. The numbers turn a vague sense of being failed into a specific, nameable failure.
And a nameable failure is one you can point at, vote on, and refuse to carry as a personal shortcoming. You don't have to become an activist to use them. You just have to stop holding a systemic problem as if it were a private one.
Where it's finally starting to move
Here's the part that keeps this from being a counsel of despair: the only reason we have 2026 numbers at all is that people finally started measuring. You cannot publish a “Women's Health Investment Outlook” for a category nobody was tracking a few years ago. New funds, new startups, new research are appearing specifically in the midlife gap — not because the world suddenly grew a conscience, but because someone did the math and saw a trillion-dollar opportunity sitting untouched. That's slow, and it's late, and it's real. The gap got named. Named things get closed.
Why this lands in your body, not just a spreadsheet
It's tempting to file all this under “politics” and move on, because funding charts feel far away from a bad night's sleep. But the distance is an illusion. The reason there's no clear protocol for your brain fog is that almost no one funded the research to build one. The reason your doctor reached for an antidepressant instead of a plan is that the plan was never developed. The reason you spent two years thinking you were losing your mind is that the science that would reassure you in a single appointment doesn't exist yet — because the money went elsewhere. The gap isn't abstract. It's the specific, personal silence you've been living inside.
So when you repeat these numbers — to your doctor, your daughter, your representative — you're not being political. You're doing maintenance on the world your future self, and every woman coming up behind you, is going to have to live in. Closing the gap is the difference between the next generation getting answers in twenty minutes and getting exactly what you got.
The bottom line
It was never that your body was too complicated to study. It was that the money went to the years when you were making babies and the years when you might get cancer — and skipped the long, powerful middle where you actually live.
You're not crazy, and you're not imagining the silence. There's a funding map, and you've been standing in its blank spot your whole midlife. Now you can see it — and a gap you can see is a gap you can close.
— Delaney
Sources & References
1. World Economic Forum — Women's Health Investment Outlook (Jan 2026): ~6% of private healthcare investment to women's health; ~90% into women's cancers, reproductive and maternal health; <2% to endometriosis, PCOS and menstrual health; women spend ~25% more of their lives in poor health.
2. NIH RePORT (categorical spending) — menopause research ~$56M/yr (~0.12% of the NIH budget).
3. Startup/VC funding analysis — erectile dysfunction ~$1.24B vs endometriosis ~$44M (≈28:1). WHO — 190M women worldwide with endometriosis.
4. McKinsey Health Institute & WEF (2024) — closing the women's health gap would add ≥$1 trillion/yr by 2040; ~75M healthy life-years lost annually.
-
Women's health receives about 6% of private healthcare investment, and roughly 90% of that goes to just three areas — women's cancers, reproductive and maternal health. Endometriosis, PCOS and menstrual health together get under 2%. U.S. menopause research is about $56 million a year, ~0.12% of the NIH budget.
Key takeaways:
• Women's health gets ~6% of private healthcare investment; ~90% of that goes to cancers, reproductive and maternal health (WEF, 2026).
• Endometriosis, PCOS and menstrual health together receive under 2% of women's health investment.
• U.S. menopause research is ~$56M/yr — about 0.12% of the NIH budget.
• Closing the women's health gap could add ≥$1 trillion/yr by 2040 and recover ~75M healthy life-years (McKinsey/WEF).
-
About 6% of private healthcare investment (WEF, 2026), despite women being over half the population.
-
About 90% of women's health investment goes to cancers, reproduction and maternity — the fertile years and cancer — leaving midlife conditions like menopause in the gap.
-
About $56 million a year from the NIH, roughly 0.12% of its budget.
-
In startup/VC funding, erectile dysfunction drew ~$1.24B versus ~$44M for endometriosis — about 28 to 1.
-
Yes — an estimated ≥$1 trillion a year by 2040 (McKinsey/WEF).
-
No — educational only; talk to your provider about your care.
